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ABSTRACT
The relationship between susceptibility to macrolides and tetracycline, and the distribution of the
resistance genes erm(B), mef(A) and tet(M) and the integrase gene of the conjugative transposon, Int-Tn,
was examined in 43 isolates of Streptococcus pneumoniae from Gunma Prefecture, Japan. Thirty-ﬁve
isolates were resistant to both macrolides and tetracycline and carried tet(M); erm(B) and mef(A) were
detected in 19 and 16, respectively, of these isolates. Sixteen mef(A)-positive isolates were all identiﬁed
as mef(E) variants. Int-Tn of Tn1545 was associated with 17 erm(B)- and 14 mef(A)-bearing isolates, and
Int–Tn of Tn5252 was found in the remaining two mef(A)-carrying isolates. Pneumococcal strains with
resistance to macrolides conferred by erm(B) or mef(A) in association with the integrase gene of
conjugative transposon Tn1545 or Tn5252 appear to be prevalent in Japan.
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INTRODUCTION
Streptococcus pneumoniae is one of the most
important bacterial pathogens causing respiratory
tract infections such as community-acquired
pneumonia and otitis media, bacteraemia and
meningitis. Treatment of pneumococcal infections
is becoming difﬁcult because of dissemination of
penicillin-resistant strains and the rapid develop-
ment of resistance to other antibiotics, including
macrolides [1].
There are two principal mechanisms of macro-
lide resistance, namely target site modiﬁcation
and active efﬂux. Target site modiﬁcation is
mediated by a methylase, which methylates a
speciﬁc adenine residue on 23S rRNA. In pneu-
mococci, this enzyme is encoded by erm(B) [2,3],
which is expressed in either an inducible or a
constitutive manner. Active induction of erm(B)
occurs with 14-membered (e.g., erythromycin and
clarithromycin) or 15-membered (e.g., azithromy-
cin) macrolides, lincosamides and streptogramin
B. In contrast, rokitamycin, a 16-membered
macrolide, does not induce gene expression in
many resistant strains carrying erm(B) [4,5]. The
second mechanism involves an active efﬂux
pump, which removes 14- and 15-membered
macrolides, but not 16-membered macrolides,
from bacterial cells. This efﬂux pump is encoded
by mef(A), and isolates carrying mef(A) are sus-
ceptible to rokitamycin, lincosamides and strep-
togramin B [4,5].
The recent emergence of multiple-antibiotic
resistance in S. pneumoniae has been associated
with the conjugative transposon Tn1545, which
confers resistance to tetracycline, kanamycin
and macrolides, encoded by tet(M), aphA-3 and
erm(B), respectively, and is self-transmissible to a
wide variety of Gram-positive bacteria [6].
Another conjugative transposon, Tn5252, which
confers chloramphenicol resistance, has also been
found in S. pneumoniae [7]. Conjugative trans-
posons contain an Int-Tn gene, which encodes an
Corresponding author and reprint requests: T. Shiojima,
Department of Pediatrics, Gunma University School of Medi-
cine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan
E-mail: tsiojima@showa.gunma-u.ac.jp
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
integrase that is essential for the integration of the
genetic element into chromosomal DNA during
conjugation. Since the Int-Tn sequence of Tn1545
(Int-Tn1545) differs from the Int-Tn sequence of
Tn5252 (Int-Tn5252), it is possible to design PCR
primer sets targeted at each sequence [8,9].
The present study investigated the susceptibil-
ity of S. pneumoniae isolates in Japan to macro-
lides, tetracycline and other antibiotics. The
distribution of resistance genes and integrase
genes was examined by PCR, using primer sets
speciﬁc for tet(M), erm(B), mef(A), Int-Tn1545 and
Int-Tn5252, and serotypes were determined. In
addition, the presence of mef(A) and mef(E) var-
iants [5] was determined using speciﬁc PCR
primers [10].
MATERIALS AND METHODS
Bacterial isolates
Between January and April 2002, 43 non-duplicate clinical
isolates of S. pneumoniae were collected from nine medical
centres in Gunma Prefecture, Japan, from sputum, pharyngeal
swab, nasal mucus and other specimens. Identiﬁcation was
based on Gram’s stain, colonial morphology and haemolysis
on blood agar medium, susceptibility to optochin disks and
detection of an autolysin gene by PCR [11].
Antibiotics and susceptibility tests
The antibiotics used were erythromycin, clarithromycin,
azithromycin, rokitamycin, lincomycin, chloramphenicol and
tetracycline. MICs were determined by agar dilution [12]
using Muller–Hinton agar (Difco, Tokyo, Japan) supplemen-
ted with horse serum 5% v ⁄v. Inocula were prepared from
cells grown freshly in brain–heart infusion broth, with
c. 104 CFU ⁄ spot.
Detection of macrolide and tetracycline resistance genes and
integrase genes of conjugative transposons by PCR
Genomic DNA was extracted from each isolate by incubating
bacterial cell suspensions at 60C for 10 min, followed by 90C
for 5 min; each preparation was then assayed for the presence
of erm(B), mef(A) and tet(M) by PCR. The oligonucleotide
primers were as follows: for erm(B), 5¢-CGTACCTTGGAT-
ATTCACCG-3¢ (forward) and 5¢-GTAAACAGTTGACGA-
TATTCTCG-3¢ (reverse) [13]; for mef(A), 5¢- GGGACCTGC-
CATTGGTGTGC-3¢ (forward) and 5¢-CCCAGCTTAGGTA-
TACGTAC-3¢ (reverse) (this article); and for tet(M), 5¢-GA-
ACTGTATCCTAATGTGTG-3¢ (forward) and 5¢-GATACTC-
TAACCGAATCTCG-3¢ (reverse) [14]. To distinguish mef(A)
from mef(E), primers 5¢-TGGTTCGGTGCTTACTATTGT-3¢
(forward) and 5¢-CCCCTATCAACATTCCAGA-3¢ (reverse)
were used for mef(A), and 5¢-GGGAGATGAAAGAA-
GGAGT-3¢ (forward) and 5¢-TAAAATGGCACCGAAAG-3¢
(reverse) were used for mef(E) [10]. To detect Int-Tn genes,
primers 5¢-GCTCAAAGACCAAAGGTTAGAA-3¢ (forward)
and 5¢-TGTGTGGCAATTTATCCTCGTT-3¢ (reverse) were
used for Int-Tn1545 [8], and primers 5¢-TTAAGTTCTCTCC-
TATGACTGC-3¢ (forward) and 5¢-AAGTCTTTGAACTCA-
TCGACAC-3¢ (reverse) were used for Int-Tn5252 [9]. Each
50-lL reaction mixture contained 5 lL of template DNA, 10 lL
(10 pmol) of each forward and reverse primer, and 25 lL of
PCR reaction kit mixture (Takara, Tokyo, Japan). Gene ampli-
ﬁcation was performed using a PC-700 thermal cycler (Astec,
Tokyo, Japan) at 94C for 5 min, followed by 35 cycles of 94C
for 1 min, 50C or 54C for 1 min, and 72C for 1 min
[8–10,13,14].
Serotyping
Serotyping was performed by agglutination with polyvalent
and monovalent antisera for S. pneumoniae capsules (Denka
Seiken, Tokyo, Japan). One drop of each antiserum was placed
on a glass slide and mixed with a visible amount of
pneumococcal cells. Physiological saline was used as a control
instead of an antiserum.
RESULTS
Detection of macrolide resistance genes by PCR
and susceptibility testing
PCR revealed that 19 (44.2%) and 16 (37.2%) of
the 43 isolates of S. pneumoniae carried erm(B) and
mef(A), respectively. Eight (18.6%) isolates did not
carry any resistance gene, and no isolate carried
both genes (Table 1). Typical PCR ampliﬁcation
products of mef(A) and erm(B) are shown in Fig. 1
(lanes 1 and 2). Further PCRs with primer sets
speciﬁc for either mef(A) or mef(E) [10] revealed
Table 1. Antibiotic resistance patterns, genotypes and serotypes (or serogroups) for 43 Streptococcus pneumoniae isolates
from Japan
Resistance pattern
Genotype Serotype (or serogroup)
erm(B) mef(A) tet(M) Int-Tn1545 Int-Tn5252 3 6 9 14 19 22 23 35 NT Total no.
Mac, Lcm, TET, CHL + – + + – 7 1 2 10
Mac, Lcm, TET + – + + – 1 1 1 4 7
Mac, Lcm, TET + – + – – 2 2
Mac, TET – + + + – 4 1 8 1 14
Mac, TET – + + – + 2 2
Susceptible – – – – – 2 2 1 2 1 8
Mac, macrolides; Lcm, lincomycin; TET, tetracycline; CHL, chloramphenicol; NT, non-typeable.
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that all 16 mef(A)-carrying isolates were mef(A)-
negative but mef(E)-positive; i.e., they were mef(E)
variants.
The relationship between antibiotic suscepti-
bility and macrolide resistance genes is shown in
Fig. 2. Eight isolates in which no macrolide
resistance gene was detected by PCR were
susceptible to all of the antibiotics examined.
Among the 19 isolates carrying erm(B), ﬁve were
intermediately-resistant to erythromycin, while
the remaining 14 were highly-resistant (MICs
> 128 mg ⁄L). Eight and 13 isolates showed high-
level resistance to clarithromycin and azithromy-
cin, respectively. One isolate was highly-resistant
to rokitamycin, 12 were intermediately-resistant
and six were susceptible. Levels of resistance to
lincomycin were slightly higher than those for
erythromycin or azithromycin. All of the erm(B)
isolates were resistant to tetracycline, and ten
were resistant to chloramphenicol (Fig. 2).
All 16 isolates carrying mef(A) were intermedi-
ately-resistant to erythromycin, clarithromycin
and azithromycin, susceptible to rokitamycin,
lincomycin and chloramphenicol, and resistant
to tetracycline (Fig. 2). The MICs of kanamycin
for the 43 isolates ranged from 32 to 128 mg ⁄L,
indicating that they did not acquire a gene
conferring kanamycin resistance (data not
shown).
Detection of tet(M) and Int-Tn by PCR
The antibiotic resistance patterns and genes for
antibiotic resistance and conjugation are shown in
Table 1. The tet(M) gene was detected in 35
isolates, which were resistant to tetracycline and
carried either erm(B) or mef(A), but was not
ampliﬁed from isolates susceptible to tetracycline
and macrolide.
Int-Tn1545 was ampliﬁed from 31 (72.1%) of
the 43 isolates. Among these 31 isolates, ten were
resistant to macrolides, lincomycin, tetracycline
and chloramphenicol, and seven were resistant to
macrolides, lincomycin and tetracycline; these 17
isolates carried erm(B). The remaining 14 isolates
were resistant to macrolides and tetracycline, and
carried mef(A) (Table 1). PCR was performed for
Int-Tn5252, using DNA prepared from four iso-
lates carrying tet(M) and either erm(B) or mef(A),
but not Int-Tn1545. Int-Tn5252 was detected in
two isolates carrying mef(A) (Table 1). Represen-
tative amplicons for tet(M), Int-Tn1545 and Int-
Tn5252 are shown in Fig. 1.
Serotyping
Serotypes for the isolates are shown in Table 1.
The isolates belonged to serotype 3 (n = 8),
serogroups 6 (n = 10) and 9 (n = 1), serotype 14
(n = 1), and serogroups 19 (n = 10), 22 (n = 1), 23
(n = 5) and 35 (n = 2), with ﬁve isolates being
non-typeable. Among the eight isolates belonging
to serotype 3, seven were resistant to chloram-
phenicol and all carried erm(B). Serogroup 19 was
not found among the 19 erm(B)-carrying isolates,
whereas eight of 16 mef(A)-carrying isolates
belonged to serogroup 19 (Table 1).
DISCUSSION
Macrolide resistance in S. pneumoniae has
increased in European countries, e.g., Italy,
1 2 3 4M
500 bp
300 bp
800 bp
Fig. 1. Examples of amplicons obtained following speciﬁc
PCRs for detection of drug resistance and Int-Tn genes.
Lanes: M, size marker; 1, mef(A), 402 bp; 2, erm(B), 224 bp;
3, Int-Tn1545, 742 bp, and tet(M), 377 bp; 4, Int-Tn5252,
877 bp.
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France and Spain, as well as in North America.
In Asia, the incidence of erythromycin-resistant
S. pneumoniae has risen in Hong Kong, Taiwan
and Japan to nearly 80% [15]. A high incidence
of macrolide resistance was conﬁrmed in the
present study, with 81.4% (35 ⁄ 43) of the isolates
being resistant to 14-membered macrolides
(erythromycin and clarithromycin) and a 15-
membered macrolide, azithromycin. In contrast,
70% (30 ⁄ 43) of isolates were susceptible to
rokitamycin, a 16-membered macrolide used
clinically in Japan, which is expected to be used
no resistance : 8 strains
erm (B) : 19 strains
mef (A) : 16 strains
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Fig. 2. Distribution of the erm(B)
and mef(A) macrolide resistance
genes according to MICs of various
antibiotics.
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widely for the treatment of pneumococcal
infections.
Wide geographical differences in the distribu-
tion of erm(B) and mef(A) throughout the world
have been reported [16]. Nishijima et al. [17]
reported that isolates carrying erm(B), mef(A) or
both genes comprised 44%, 40% and 16%,
respectively, of erythromycin-resistant isolates
from Japan in 1995. In the present study, 54% of
erythromycin-resistant isolates carried erm(B),
and the remaining 46% carried mef(A), but none
carried both genes. Therefore, the prevalences of
erm(B) and mef(A) in Japan appear to be similar.
In S. pneumoniae, conjugative transposons, such
as Tn1545, play a role in the horizontal spread of
isolates resistant to multiple antibiotics, including
macrolides. In Spain, pneumococcal DNA pre-
pared from isolates carrying both erm(B) and
tet(M) hybridised with an Int-Tn probe in 87% of
cases, while the DNA from mef(A) and tet(M)
isolates hybridised with the probe in 29% of cases
[18]. In the present study, Int-Tn1545 was ampli-
ﬁed from 90% and 88% of isolates carrying erm(B)
and mef(A), respectively. In addition, Int-Tn5252
was detected in two isolates carrying mef(A).
Grosso et al. [19] have reported that erythromycin
resistance encoded by mef(A) could be transferred
by conjugation between S. pneumoniae isolates,
although the mechanisms and molecular basis of
this conjugative transfer of mef(A) remained
unclear. These results strongly suggest that, in
addition to pneumococcal strains carrying the
Tn1545-like element-associated erm(B) gene,
strains that harbour a genetic element which has
evolved from Tn1545 or Tn5252, and that confers
macrolide resistance mediated by mef(A), have
also spread in Japan.
Serotyping of the S. pneumoniae isolates sug-
gested that serotype (or serogroup) 3, 6, 19 and 23
isolates were prevalent in Japan, as reported by
Ubukata et al. [20]; eight of 43 isolates in the
present study belonged to serotype 3 and carried
tet(M) and erm(B), but not mef(A). Daly et al. [10]
distinguished the efﬂux genes responsible for
macrolide resistance as either mef(A) or mef(E),
and reported, in a worldwide survey of macro-
lide-resistant S. pneumoniae isolates, that most
mef(E) isolates were grouped into four serotypes
(or serogroups), namely 19, 6, 14 and 23 in order
of isolation. Among these isolates, all ten isolates
from Asia carried mef(E) but not mef(A), and
belonged to serogroup 19. The efﬂux genes of
16 isolates in the present study were identiﬁed as
mef(E), and most of these isolates belonged to
serogroups 19 (n = 8) and 6 (n = 6). These ﬁnd-
ings suggest worldwide dissemination of macro-
lide-resistant S. pneumoniae carrying mef(E) which
belong to serogroup 19.
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